AZD3632, AZD3632
D8620C00001
Phase 2 small_molecule active
Quick answer
AZD3632, AZD3632 for Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active